Start Over

Von Willebrand factor, ADAMTS13 and mortality in dialysis patients.

Authors :: Ocak G
Roest M
Verhaar MC
Rookmaaker MB
Blankestijn PJ
Bos WJW
Fijnheer R
Péquériaux NC
Dekker FW
Source :: BMC nephrology [BMC Nephrol] 2021 Jun 16; Vol. 22 (1), pp. 222. Date of Electronic Publication: 2021 Jun 16.
Publication Year :: 2021
Abstract: Background: Von Willebrand Factor (VWF) multimers are cleaved into smaller and less coagulant forms by the metalloprotease ADAMTS13. The aim of this study was to investigate the association between VWF and ADAMTS13 and mortality in dialysis patients.<br />Methods: We prospectively followed 956 dialysis patients. VWF levels and ADAMTS13 activity were measured. Cox proportional hazard analyses were used to calculate hazard ratios (HRs) with 95 % confidence intervals (CIs) to investigate the association between quartiles of VWF levels and ADAMTS13 activity and all-cause mortality. HRs were adjusted for age, sex, body mass index, cardiovascular disease, dialysis modality, primary kidney disease, use of antithrombotic medication, systolic blood pressure, albumin, C-reactive protein and residual GFR.<br />Results: Of the 956 dialysis patients, 288 dialysis patients died within three years (mortality rate 151 per 1000 person-years). The highest quartile of VWF as compared with lower levels of VWF was associated with a 1.4-fold (95 %CI 1.1-1.8) increased mortality risk after adjustment. The lowest quartile of ADAMTS13 activity as compared with other quartiles was associated with a 1.3-fold (95 %CI 1.0-1.7) increased mortality risk after adjustment. The combination of the highest VWF quartile and lowest ADAMTS13 quartile was associated with a 2.0-fold (95 %CI 1.3-3.0) increased mortality risk as compared with the combination of the lowest VWF quartile and highest ADAMTS13 quartile.<br />Conclusions: High VWF levels and low ADAMTS13 activity were associated with increased mortality risks in dialysis patients.